An Electrophysiological Study Of E2014 In Healthy Adult Male Japanese And Caucasian Subjects

Inclusion criteria

• Participants aged between 20 and 44 years at the time of obtaining informed consent.
• Participants whose M wave amplitude potential (between baseline and negative peak) in the EDB by stimulating peroneal nerve in the foot joints is 1 mV or more during electrophysiological examinations at the times of screening and immediately before administration.
• Participants who are judged to be eligible for study entry by an investigator or subinvestigator at screening and at immediately before pre-treatment medical examination.
• Participants who are given a full explanation about the objective and details of this study before starting screening and give written consent based on their free will.

Exclusion Criteria

• Participants who have a complication or history of peripheral neuropathy, nerve root impairment, muscle disease.
• Participants with a disease that may influence the study drug evaluation, such as disorders of the gastrointestinal tract, liver, respiratory, endocrine, hematological, neurological, psychiatric and cardiovascular system, and congenital abnormality in metabolism.
• Participants who have accessory deep peroneal nerve.
• Participants who previously received a treatment with botulinum toxin.
• Participants with a history of hypersensitivity to any component of E2014 (human serum albumin, succinate buffer solution).
• Participants who are positive for urine drug screening at the time of screening or immediately before study drug administration.
• Participants who received prescription drug(s) within 1 month before study drug administration.
• Participants who have been treated with another investigational drug within 4 months before study drug administration.
• Participants who have experienced heavy exercise or hard labor within 2 weeks before study drug administration.
• Participants who underwent blood transfusion within 3 months before, those whose 400 mL of whole blood was collected within 3 months before, or those whose 200 mL of whole blood was collected within 1 month before study drug administration.
• Participants who are positive for hepatitis B surface antigen (HBs antigen), hepatitis C virus (HCV) antibody, or serologic test for syphilis (STS).
• Participants who received a diagnosis of acquired immunodeficiency syndrome (AIDS) or those with positive result for human immunodeficiency virus.
• Participants who are unwilling or unable to abide by the requirements of this study, or those who may violate the prohibitions and restrictions of this study.
• Participants who are judge to be ineligible for study entry by a principal investigator or subinvestigator.